Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nimble Collaborates with Genentech | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Nimble Collaborates with Genentech

Collaboration will discover and develop novel peptide-based therapeutics

By: Tiffany Coppolino

Nimble Therapeutics is collaborating with Genentech, a member of the Roche Group, to accelerate discovery and development of novel peptide-based medicines for targets across a range of diseases.
 
The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, chemical diversity, and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.
 
“We are excited to collaborate with a world class and well-respected organization such as Genentech to identify novel peptide therapeutics,” said Jigar Patel, chief executive officer, Nimble Therapeutics. “This partnership combines the strengths of our two organizations to potentially bring new medicines to patients.”
 
Under the terms of the agreement, Nimble will receive an undisclosed upfront payment and will be eligible for downstream milestone payments and royalties.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics